In vitro activity of cefditoren versus other antibiotics against S. pneumoniae clinical strains isolated in Italy

International Journal of Immunopathology and Pharmacology

Volumn 23, Issue 3, 2010, Pages 833-840

  Tempera, Gianna ^a   Furneri, P M ^a   Ferranti, C ^a   Genovese, C ^a   Ripa, S ^b   Ungheri, S ^c   Nicoletti, G ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b UNIVERSITY OF CAMERINO   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

Cefditoren; In vitro activity; S. Pneumoniae

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AZITHROMYCIN; CEFACLOR; CEFDITOREN; CEFIXIME; CEFPODOXIME; CEFTIBUTEN; CEFUROXIME; CLARITHROMYCIN; ERYTHROMYCIN; LEVOFLOXACIN; PENICILLIN G;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; DRUG ACTIVITY; IN VITRO STUDY; ITALY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIAE;

EID: 78149274968     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463201002300318     Document Type: Article

References (38)

1. Johnson DM, Biedenbach DJ, Beach ML, Pfaller MA, Jones RN. Antimicrobial activity and in vitro susceptibility test development for cefditoren against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus species. Diagn Microbiol Infect Dis 2000; 37:99-105.
2. Blasi F, Farrell DJ, Dubreuil L. Antibacterial activity of telithromycin and comparators against pathogens isolated from patients with community-acquired respiratory tract infections: the Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin. Diagn Microbiol Infect Dis 2009; 63:302-8
3. Stefani S, Mezzatesta ML, Fadda G, Mattina R, Palù G, Rossano F, Tufano MA, Schito GC, Nicoletti G. Antibacterial activity of cefditoren against major community-acquired respiratory pathogens recently isolated in Italy. J Chemother 2008; 20:561-69
4. Clinical and Laboratory Standards Institute, 2008 Clinical and Laboratory Standards Institute, Performance standards for antimicrobial susceptibility testing, 18th informational supplement, M100-S19, CLSI, Wayne, PA (2008).
5. Clinical and Laboratory Standards Institute, 2009 Clinical and Laboratory Standards Institute, Performance standards for antimicrobial susceptibility testing, 19th informational supplement, M100-S19, CLSI, Wayne, PA (2009).
6. CDC Effects of New Penicillin Susceptibility Breakpoints for Streptococcus pneumoniae - United States, 2006-2007. MMWR 2008; 57:1353-55.
7. Woodhead M, Blasi F, Ewig S, et al. Guidelines for the management of adult lower respiratory tract infections. Eur Respir J 2005; 26:1138-80
8. Burgess DS, Lewis JS. Effect of macrolides as part of initial empiric therapy on medical outcomes for hospitalized patients with community-acquired pneumonia. Clin Ther 2000; 22:872-78
9. Mazzei T, Novelli A. Cefditoren Pivoxil: Una nuova cefalosporina orale per il trattamento delle infezioni respiratorie comunitarie. Farmaci Terapia 2008; XXV:1-20.
10. Clark CL, Nagai K, Dewasse BE, Pankuch GA, Ednie LM, Jacobs MR, Appelbaum PC. Activity of cefditoren against respiratory pathogens. J Antimicrob Chemother 2002; 50:33-41
11. Jones RN, Biedenbach DJ, Croco MA, Barrett MS. In vitro evaluation of a novel orally administered cephalosporin (cefditoren) tested against 1249 recent clinical isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae. Diagn Microbiol Infect Dis 1998; 31:573-78
12. Jones RN, Pfaller MA, Jacobs MR, Appelbaum PC, Fuchs PC. Cefditoren in vitro activity and spectrum: a review of international studies using reference methods. Diagn Microbiol Infect Dis 2001; 41:1-14.
13. Sader HS, Jacobs MR, Fritsche TR. Review of the spectrum and potency of orally administered cephalosporins and amoxicillin/clavulanate. Diagn Microbiol Infect Dis 2007; 57:S5-S12.
14. Wellington K, Curran MP. Spotlight on cefditoren pivoxil in bacterial infections. Treat Respir Med 2005; 4:149-52.
15. Sakano T, Nejihashi N, Furue T, Kinoshita Y, Ono H, Ohta T. Changes in the drug resistance of Haemophilus influenzae and Streptococcus pneumoniae isolated between 1997 and 2006. Kansenshogaku Zasshi 2009; 83:347-54.
16. Nagai K, Davies TA, Jacobs MR, Appelbaum PC. Effects of amino acid alterations in penicillin-binding proteins (PBPs) 1a, 2b, and 2x on PBP affinities of penicillin, ampicillin, amoxicillin, cefditoren, cefuroxime, cefprozil, and cefaclor in 18 clinical isolates of penicillin-susceptible, -intermediate, and -resistant pneumococci. Antimicrob Agents Chemother 2002; 46:1273-80.
17. Yamada M, Watanabe T, Miyara T, Baba N, Saito J, Takeuchi Y, Ohsawa F. Crystal structure of cefditoren complexed with Streptococcus pneumoniae penicillin-binding protein 2X: structural basis for its high antimicrobial activity. Antimicrob Agents Chemother 2007; 51:3902-07.
18. Biedenbach DJ, Jones RN. Update of cefditoren activity tested against community-acquired pathogens associated with infections of the respiratory tract and skin and skin structures, including recent pharmacodynamic considerations. Diagn Microbiol Infect Dis 2009; 64:202-12.
19. Sader HS, Jacobs MR, Fritsche TR. Review of the spectrum and potency of orally administered cephalosporins and amoxicillin/clavulanate. Diagn Microbiol Infect Dis 2007; 57(S):5-12.
20. Seral C, Suárez L, Rubio-Calvo C, et al. In vitro activity of cefditoren and other antimicrobial agents against 288 Streptococcus pneumoniae and 220 Haemophilus influenzae clinical strains isolated in Zaragoza, Spain. Diagn Microbiol Infect Dis 2008; 62:210-15.
21. Lee MY, Ko KS, Oh WS, et al. In vitro activity of cefditoren: antimicrobial efficacy against major respiratory pathogens from Asian countries. Int J Antimicrob Agents 2006; 28:14-8.
22. Sutcliffe J, Grebe T, Tait-Kamradt A, Wondrack L. Detection of erythromycin-resistant determinants by PCR. Antimicrob Agents Chemother 1996; 40:2562-66.
23. Seppälä H, Skurnik M, Soini H, Roberts MC, Huovinen P. A novel erythromycin resistance methylase gene (ermTR) in Streptococcus pneumonia. Antimicrob Agents Chemother 1998; 42:257-62.
24. Klaassen CHW, Mouton JW. Molecular detection of the macrolide efflux gene: to discriminate or not to discriminate between mef(A) and mef(E). Antimicrob Agents Chemother 2005; 49:1271-78.
25. Jenkins SG, Farrel DJ. Increase in pnemococcus macrolide resistance, United States. Emerg Infect Dis 2009; 15:1260-64.
26. Reinert RR. The antimicrobial profile of Streptococcus pneumoniae. Clin Microb Infect 2009; 15(S):7-11.
27. Goosenns H. Antibiotic consumption and link to resistance. Clin Microb Infect 2009; 15(S):12-15.
28. Jones RN, Fritsche TR, Sader HR. Therapeutic options among broad-spectrum β-lactams for infections caused by levofloxacin-nonsusceptible Streptococcus pneumoniae. Diagn Microbiol Infect Dis 2005; 52:129-33.
29. Deshpande LM, Sader HS, Debbia E, Nicoletti G, Fadda G, Jones RN. Emergence and epidemiology of fluoroquinolone-resistant Streptococcus pneumoniae strains from Italy: report from the SENTRY Antimicrobial Surveillance Program (2001-2004). Diagn Microbiol Infect Dis 2006; 54:157-64.
30. Montagnani F, Stolzuoli L, Zanchi A, Cresti S, Cellesi C. Antimicrobial susceptibility of Streptococcus pyogenes and Streptococcus pneumoniae: surveillance from 1993 to 2004 in Central Italy. J Chemother 2006; 18:389-93.
31. Mazzariol A, Koncan R, Bahar G, Cornaglia G. Susceptibilities of Streptococcus pyogenes and Streptococcus pneumoniae to macrolides and telithromycin: data from an Italian multicenter study. J Chemother 2007; 19:500-7.
32. Montagnani F, Fanetti A, Stolzuoli L, Croci L, Arena F, Zanchi A, Cellesi C. Pneumococcal disease in a pediatric population in a hospital of central Italy: a clinical and microbiological case series from 1992 to 2006. J Infect 2008; 56:179-84.
33. Fenoll A, Robledo O, Lerma M, Giménez MJ, Cebriàn L, Casal J, Aguilar L, Gomez-Lus ML. Activity of cefpodoxime and other oral beta-lactams against Haemophilus influenzae and Streptococcus pneumoniae with different susceptibilities to penicillin. Rev Esp Quimioter 2006; 19:39-44.
34. Pérez-Trallero E, Marimón JM, Ercibengoa M, Giménez MJ, Coronel P, Aguilar L. Antimicrobial susceptibilities of amoxicillin-non- susceptible and susceptible isolates among penicillin-non-susceptible Streptococcus pneumoniae. Clin Microbiol Infect 2007; 13:937-40.
35. Fenoll A, Giménez MJ, Robledo O, Aguilar L, Tarragó D, Granizo JJ, Martín-Herrero JE. Influence of penicillin/amoxicillin non-susceptibility on the activity of third-generation cephalosporins against Streptococcus pneumoniae. Eur J Clin Microbiol Infect Dis 2008; 27:75-80. (Pubitemid 350197876)
36. Fritsche TR, Biedenbach DJ, Jones RN. Update of the activity of cefditoren and comparator oral beta-lactam agents tested against community-acquired Streptococcus pneumoniae isolates (USA, 2004-2006). J Chemother 2008; 20:170-4.
37. Fenoll A, Giménez MJ, Robledo O, Aguilar L, Tarragó D, Granizo JJ, Gimeno M, Coronel P. In vitro activity of oral cephalosporins against pediatric isolates of Streptococcus pneumoniae non-susceptible to penicillin, amoxicillin or erythromycin. J Chemother 2008; 20:175-9.
38. Varaldo PE, Montanari MP, Giovanetti E. Genetic elements responsible for erythromycin resistance in streptococci. Antimicrob Agents Chemother 2009; 53:343-53.